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OBJECTIVE: A general vaccination of newborns with PnC-7
reduces pneumococcal diseases and also the rate of pneumococ-
cal diseases in unvaccinated adults (herd immunity). Usually
cohort of patients followed subsequent cycles in a Markov
model. In this study, age and class were computed cross sec-
tionally. The objective of this study was to evaluate the annual
health outcomes and cost-effectiveness of a general vaccination
with PnC-7 in a hypothetical steady state German cohort across
all age groups with base year 2003 focusing health care payers’
perspective. METHODS: The efﬁcacies of PnC-7 and herd
immunity were adjusted to serotype distribution according to
two German panels. The model included incidences of pneumo-
coccal diseases, fatality rates, rate of long-term sequelae, age spe-
ciﬁc German population structure, 3 + 1 application of PnC-7,
and health care expenditures for treatment of pneumococcal dis-
eases. Critical key data were varied in a sensitivity analysis.
RESULTS: A vaccination rate PnC-7 of 68% is able to avoid
4256 invasive pneumococcal diseases, 57,727 pneumococcal
pneumonias, 274,332 cases of otitis media, 99 longterm seque-
laes and 2257 deaths resulting in 34,237 life years gained in
Germany every year. From health care payer’s view the cost
savings outweighed the vaccination administration with factor
1.23 and costs of a life-year-saved are 887€. The one-way sensi-
tivity analysis showed the estimations were sensitive to reduction
in incidence of otitis media and health care costs, but the vacci-
nation with PnC-7 remained cost saving. On the other hand, the
incorporation of an ageing German population, 2 + 1 applica-
tion of PnC-7, herd immunity without serotype adjustments or
non-discounting of life year gained resulted in conservative cost-
effectiveness estimations. CONCLUSIONS: From the German
health care payer view, a general vaccination with conjugate
vaccine PnC-7 is cost saving.
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THE COST-EFFECTIVENESS OF EXPANDING NEWBORN
SCREENING FOR INHERITED METABOLIC DISORDERS USING
TANDEM MASS SPECTROMETRY
Cipriano LE, Rupar CA, Zaric GS
University of Western Ontario, London, ON, Canada
OBJECTIVES: Currently, newborns in Ontario, Canada, are
screened for phenylketonuria (PKU) using the Guthrie method.
Tandem mass spectrometry (MS/MS) can allow several other
metabolic diseases to be screened for at birth. We estimated the
costs, health beneﬁts, and cost-effectiveness of using MS/MS to
expand the newborn screening program in Ontario to include 20
additional metabolic diseases. METHODS: We constructed a
decision-analytic model to estimate the incremental costs and life
years of survival gained associated with screening by MS/MS
versus the status quo (either not screening or screening with a
different technology). Disease prevalence, test characteristics,
treatment effectiveness, disease progression rates, and mortality
were estimated from secondary sources and expert opinion.
Costs were estimated primarily from the London Health Sciences
Center Case Costing Initiative, the Ontario Health Insurance
Plan Schedule of Beneﬁts, and the Ontario Drug Beneﬁts Plan
formulary. Costs and health beneﬁts were estimated for a cohort
of babies born in Ontario in one year. RESULTS: Using MS/MS
to screen for PKU has an incremental cost of $2,800,000 per life
year (LY) gained. When each additional disease was evaluated
independently, the cost of screening with MS/MS ranged from
cost-saving to $158,000/LY gained. Using MS/MS to screen for
PKU and 16 additional diseases costs $17,100/LY gained. CON-
CLUSIONS: Newborn screening reduces morbidity, mortality,
and the social burden of irreversible effects of disease on the pop-
ulation. The severity and onset of disease symptoms can be pre-
vented through early diagnosis and treatment. Our analysis
suggests that screening for PKU and 16 additional diseases has
an incremental cost effectiveness ratio below $50,000/LY gained.
However, it is not cost effective to screen for all diseases that can
be tested for using MS/MS.
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OBJECTIVE: To compare direct costs of treatment of children
(ages 3–17) with a diagnosis of an autism spectrum disorder
(autism) to a group of children having either a diagnosis of dia-
betes or asthma. METHODS: This was a retrospective, claims-
based study of children enrolled in the California Medicaid
(Medi-Cal) program from 1996–2002. Direct treatment costs
were based on utilization of inpatient, outpatient, pharmacy, and
ancillary services for all Medi-Cal eligible patients, starting 
six-months prior to a diagnosis of autism, diabetes, or asthma
(index date) to 12-months following a diagnosis. Medical and
prescription claims were categorized by psychiatric and non-
psychiatric services. Health care costs for autistic children were
then compared to costs from the randomly selected, gender
matched, cohorts of children with diabetes or asthma. Descrip-
tive statistics on demographics and non-parametric statistics on
costs (Kruskal-Wallis) were performed. RESULTS: The average
age of children with autism (n = 731) was 8.6 ± 4.0 years, com-
pared with diabetes (n = 731) 12.1 ± 4.3 years, and asthma (n =
731) 6.3 ± 3.0 years. A total of 75.4% of subjects were male.
Majority (37.1%) of the autism sample was White, while major-
ity of the asthma and diabetes children were Hispanic (44.1%
and 40.0%, respectively). Total median health care costs were
signiﬁcantly different among disease groups. Children with
autism had higher annual costs (pre-diagnosis: $363; post:
$1199) than children with diabetes (pre: $171; post: $649) or
asthma (pre: $147; post: $424) (all P < 0.0001). Psychiatric and
non-psychiatric cost categories were statistically signiﬁcant.
Additionally, the period prevalence for autism in this population
increased 114% over the study period, compared to a 42%
decrease in asthma and a 3% decrease in diabetes. CONCLU-
SIONS: This study estimates that autistic children incur greater
health care costs than children with diabetes or asthma. These
ﬁndings reﬂect the signiﬁcant cost of illness for autism 
relative to other chronic pediatric conditions in this Medi-Cal
population.
PIH4
THE QUALITY OF COMMUNITY PEDIATRICIAN’S
PRESCRIPTIONS
Triki N, Cohen R, Raz M
Maccabi Healthcare Services, Rishon Le Zion, Israel
There are several reasons why prescriptions for children’s med-
ications may have more mistakes than those for adults’ medica-
tions: dosage is adjusted to weight rather than being constant,
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confusion over the proper units (e.g. micrograms/milligrams),
prohibition of certain drugs for infants and poor compliance by
children Little is written in the medical literature concerning
errors in prescribing children’s medications in the community;
most reports focus on hospital prescribing habits. OBJECTIVES:
To evaluate the quality of community pediatricians’ prescrip-
tions. METHODS: On 13 randomly chosen days during a 10
month period (December, 2003 until October, 2004), a total of
312 prescriptions written by 54 pediatricians were reviewed in
four different pharmacies in the Shfela District of Macabi
Health-Care Services. The following criteria were used: the cor-
relation of the treatment prescribed to the diagnosis as stated in
the computerized medical record and the appropriateness of the
dosage for the child’s age and weight. A correct prescription was
deﬁned as one which met these criteria. An incorrect prescrip-
tion lacked one or both of these qualities. RESULTS: From the
312 prescriptions that were evaluated, 265 (83.9%) were found
to be properly written. In 29 (9.3%) the treatment prescribed
did not correlate to the recorded diagnosis, and in one (0.3%)
the dosage was incorrect. In three (0.9%) prescriptions, no
dosage was stipulated at all. In an additional 18 (5.7%), techni-
cal failures of the computerized ﬁle precluded seeing a diagno-
sis. CONCLUSION: A total of 83.9% of the prescriptions that
were reviewed were properly written. In most of those that failed
to correlate with the diagnosis, treatment was provided sympto-
matically (nose drops, antipyretic, etc.) As a result of this study,
technical failures that were identiﬁed in the information systems
were repaired. Physicians were provided information detailing
the proper use and dosage of symptomatic medications accord-
ing to age and weight.
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OBJECTIVES: To assess the utility of a new Health Employer
Data and Information Set (HEDIS) measure of quality of care 
of pediatric upper respiratory infections (URI) in an Israeli
HMO, develop a comparable measure, and estimate baseline
performance. METHODS: Data sources included physician 
visit and pharmacy purchase ﬁles. We selected physician visits 
in 2003 bearing diagnoses corresponding to ICD-9-CM 460 
(URI-nasopharyngitis), 465 (URI other/unspeciﬁed site), and 461
(sinusitis) among children ages three-months to 18 years. Visits
by children for whom antibiotics had been purchased in the pre-
ceding 30 days, or who had additional diagnoses were excluded.
Associated antibiotic use was deﬁned as purchase of any antibi-
otic prescribed by the physician who recorded the URI diagno-
sis within three days of the visit. RESULTS: A total of 160,781
ﬁrst encounters for URI or sinusitis met the inclusion criteria.
Nine percent were associated with an antibiotic purchase.
Antibiotic use for URI or sinusitis increased with age, from 4%
of visits in children under the age of one to 14% in children ages
15–18. Sixty-two percent of sinusitis, 7.1% of “nasopharyngi-
tis,” and 32% of “unspeciﬁed URI” visits were associated with
antibiotic use. CONCLUSION: Transfer of quality measures
between medical systems requires consideration of differences in
medical practice and of the ways in which diagnoses are used
and coded. In adapting the HEDIS measures of care of pediatric
upper respiratory infections, we chose to examine prescribing
practices within subgroups, as well as to explore sinusitis treat-
ment, an issue not currently addressed by HEDIS measures.
Overall antibiotic use in conjunction with diagnosis of URI in
our population was comparable to reported ﬁgures in US com-
mercial and Medicaid plans for the same year, but varied with
age and speciﬁc diagnosis. Additional attention to sinusitis treat-
ment, not currently addressed by HEDIS, is warranted.
PIH6
TESTING FOR STREPTOCOCCAL INFECTIONS IN CHILDREN
WITH PHARYNGITIS TREATED WITH ANTIBIOTICS IN A
LARGE ISRAELI HMO, 2003
Silverman BG, Hemo B, Friedman N
Maccabi Healthcare Services,Tel Aviv, Israel
OBJECTIVES: To assess the utility of a new Health Employer
Data and Information Set (HEDIS) measure for care quality in
treatment of pediatric pharyngitis in an Israeli HMO, develop 
a comparable measure, and estimate baseline performance.
METHODS: Data sources included physician visit, pharmacy
purchase and laboratory result ﬁles. We selected physician visits
in 2003 bearing diagnoses corresponding to ICD-9-CM groups
034, 462 and 463 among children ages two to 18 years. Visits
by children for whom antibiotics had been purchased in the pre-
ceding 30 days or who had additional diagnoses were excluded.
Antibiotic treatment was deﬁned as purchase within three days
of the visit of any antibiotic prescribed by the physician who
recorded the diagnosis of pharyngitis. The ﬁrst encounter
meeting inclusion criteria for each child was selected. Testing for
streptococcal infection was deﬁned as a throat culture or rapid
strep test in laboratory ﬁles, or record of throat swab or rapid
test during a visit, any time from three days prior to the visit
until three days after the visit. RESULTS: Fifty-one percent of
visits for pharyngitis among children ages 2–18 years were asso-
ciated with an antibiotic prescription. A total of 76,399 ﬁrst
encounters for pharyngitis were associated with antibiotic treat-
ment in 2003; 34% were accompanied by strep testing. Fre-
quency of testing varied by administrative region, from 30% to
39%. CONCLUSIONS: Utilization of strep testing in associa-
tion with antibiotic treatment of pediatric pharyngitis (as 
measured according to HEDIS criteria) was low in Maccabi
Healthcare Services in 2003 in comparison to performance in US
commercial and Medicaid health plans. In calculating this
measure, we assumed complete reporting of rapid strep tests per-
formed in physicians’ ofﬁces. Reﬁnement of this measure will
require verifying this assumption, as underreporting by physi-
cians would result underestimation of performance.
HEALTH—Elderly
PIH7
THE PREVALENCE OF POTENTIALLY INAPPROPRIATE
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Jiang JZ1, Fu AZ2, Perri M1
University of Georgia, Athens, GA, USA; 2University of North
Carolina, Chapel Hill, NC, USA
OBJECTIVES: This study determined the prevalence of poten-
tially inappropriate medication use in a nationally representative
sample of the non-institutionalized elderly population using the
updated Beers 2003 criteria. METHODS: Participants with age
65 years and older were selected from the Medical Expenditure
Panel Survey (MEPS) panel ﬁve for the period of January, 2000
to December, 2001, which was constituted by a series of ﬁve-
round interviews. The average duration within each round was
3.5, 5.0, 6.0, 6.0, and 3.5 months from round one to ﬁve, respec-
tively. Potentially inappropriate prescription medications were
identiﬁed using the NDC (National Drug Code). All the calcu-
lations of prevalence were adjusted by the weight variable in the
MEPS. RESULTS: Among the 1161 elderly participants in panel
